KB-0742 dihydrochloride(Cat No.:I044665)is a selective, orally bioavailable inhibitor of cyclin-dependent kinase 9 (CDK9), a key regulator of transcriptional elongation via phosphorylation of RNA polymerase II. By targeting CDK9, KB-0742 suppresses the expression of oncogenes and short-lived transcripts critical for tumor cell survival, such as MYC and MCL-1. It shows potent antiproliferative activity in preclinical models of prostate cancer and hematologic malignancies. KB-0742 dihydrochloride is currently under investigation for its potential as a targeted cancer therapy and serves as a valuable tool in studying transcriptional addiction in cancer biology.